SAWAI GROUP HOLDINGS Co., Ltd.
4887・Prime Market・Pharmaceuticals
Business
Sawai Group Holdings is a holding company that conducts research and development, manufacturing, and sales of generic drugs (off-patent pharmaceuticals), centered on its core subsidiary Sawai Pharmaceutical. The company offers approximately 700 products, including Cardiovascular Agents, Central Nervous System Agents, and Gastrointestinal Agents, and operates 6 plants and 9 manufacturing sites nationwide. Its main customers are hospitals and pharmacies via wholesalers (Medipal, Alfresa, etc.), and the company operates under a single-segment structure specialized in the domestic prescription drug market. It transitioned to a holding company structure in 2021, adding the Digital Healthcare / PHR Business (FrontAct) under its umbrella, and is advancing business expansion into the healthcare domain.
Business Model
Based on cost competitiveness derived from mass production at in-house plants, products are sold to medical institutions and pharmacies via wholesalers. To address price competition under the drug pricing system, the company combines market share capture through first-to-market launches with value-added differentiation through its "SAWAI HARMOTECH®" (Proprietary Formulation Technology). Of the ¥201,676 million in revenue, the top two wholesalers (Mediceo and Alfresa) account for approximately 40%, reflecting a sales structure heavily dependent on wholesalers.
Company Strengths
Sawai Pharmaceutical operates six plants and nine manufacturing sites nationwide, with production capacity of approximately 20.5 billion tablets (tablet equivalent) at the end of the fiscal year under review. The new solid dosage form building at the Second Kyushu Plant was completed in July 2024, adding ultimately 3.5 billion tablets of production capacity. The company aims to build an annual production system of 25 billion tablets through additional investment in the Second and Third Seima Plants, boasting an outstanding production scale within the industry.
The company offers approximately 700 products including cardiovascular agents, central nervous system agents, and gastrointestinal agents. During the fiscal year under review, it obtained manufacturing and marketing approval for 20 products across 11 active ingredients of generic drugs, and newly launched 9 products across 5 active ingredients including dapagliflozin tablets and lacosamide tablets. The company has disclosed its proprietary formulation technology, SAWAI HARMOTECH® (Proprietary Formulation Technology), positioning first-to-market launches of high-value-added products as a pillar of its competitive advantage.
Research and development expenses for the fiscal year under review totaled ¥12,388 million. The company plans total R&D investment of approximately ¥35.0 billion over the three years of its medium-term management plan, aiming to accumulate formulation technology and continuously enrich its new product pipeline. In December 2024, the company opened the Kobe Analytical Research Center, specializing in the analysis of carcinogenic nitrosamine substances, also investing in the sophistication of its quality control system.
ENVALITH's Perspective
Performance Trend
Revenue in FY2026 (ending March 2026) recovered to the ¥200,000 million range for the first time in five fiscal periods, reaching ¥201,676 million (up 6.7% year on year). Operating profit rose 292.5% year on year to ¥15,894 million, but this was mainly attributable to the reversal of a provision for litigation, etc. (¥16,902 million) recorded in the previous fiscal year; core operating profit, which reflects recurring earnings power, was ¥24,778 million (down 3.6% year on year). Profit attributable to owners of parent was ¥10,438 million (down 12.8% year on year), affected by a loss of ¥1,098 million from discontinued operations (the U.S. business). As an external factor, cost increases due to soaring energy and raw material prices and yen depreciation continued, pushing the cost of sales ratio up to 70.8% (70.2% in the previous fiscal year). For FY2027 (ending March 2026), the company forecasts core operating profit of ¥29,600 million (up 19.5% year on year), anticipating improved profitability driven by the effect of the minimum drug price increase and contributions from newly launched products.
Growth Strategy
Three pillars toward the final year of the medium-term plan: steady growth in generics, expanded production capacity, and cultivation of digital healthcare
Leveraging tailwinds from generic drug demand promotion under the Selected Medical Treatment System (introduced October 2024), the company launched 9 products across 5 active ingredients, including dapagliflozin tablets and lacosamide tablets, in December 2025. It strengthened its cardiovascular franchise through the succession of rights to Warfarin from Eisai (contract signed March 2025), aiming for revenue of ¥208,400 million (FY2027 (ending March 2027) forecast).
Following the completion of the new solid dosage form building at the Second Kyushu Plant (ultimate capacity of 3.5 billion tablets, completed July 2024), the company plans to increase capacity by 2.5 billion tablets through capital investment at the Seima No. 2 and No. 3 plants. It is also pursuing improved utilization rates at Trust Pharmatech in parallel, aiming to establish a group-wide annual production capacity of 25 billion tablets. Capital expenditures on property, plant and equipment for FY2026 (ending March 2026) were ¥13,416 million.
Through the consolidation of FrontAct as a subsidiary (June 2025), the company acquired specialized personnel and know-how in the PHR (Personal Health Record) business. It concluded a collaboration agreement on health promotion for the elderly with the Tokyo Metropolitan Government and four wards/cities within Tokyo (October 2025). Sales of the digital therapeutic (DTx) for alcohol dependence developed with CureApp commenced in September 2025. The company recorded ¥11,055 million in intangible asset acquisition expenditures and is in the process of building out its business foundation.
Through a collaboration agreement with Nichi-Iko Pharmaceutical regarding the consolidation of generic drug products (September 2025), the company is promoting the resolution of the small-volume, multi-product structure and the industry-wide establishment of stable supply systems. With a view to utilizing the fund for developing generic drug manufacturing infrastructure, the company is also advancing efforts to improve production efficiency and respond to the development of legal frameworks.
The company retired ¥33,240 million of treasury shares during the current fiscal year to optimize its capital structure. It has maintained a trend of dividend increases, with an annual dividend of ¥55 (FY2026 (ending March 2026)) and a forecast of ¥56 (FY2027 (ending March 2027)). The ratio of equity attributable to owners of the parent improved to 49.6%. The company aims to improve ROE under the medium-term plan's key theme of
Last updated: July 19, 2026